China-based InnoCare (HKG: 9969) and Keymed Biosciences Inc. (HKG: 2162) announced that an Investigational New Drug (IND) filing for CM369, a monoclonal antibody targeting C-C chemokine receptor 8 (CCR8), has been accepted for review by the National Medical Products Administration (NMPA). This potential first-in-class drug is designed to enhance tumor-targeted Treg depletion and improve anti-tumor activity.
Drug Mechanism and Development
CM369 is intended to deliver optimal tumor-targeted Treg depletion and produce an enhanced antibody-dependent cellular cytotoxicity (ADCC) effect. By relieving immunosuppression and enhancing anti-tumor immune activity, CM369 aims to treat lung cancer, digestive tract cancer, and other high-incidence advanced solid tumors. The drug can be used as a monotherapy or in combination with other therapies.
Collaborative Efforts
InnoCare and Keymed Biosciences are also collaborating on the development of CM355, a bispecific antibody targeting CD20 and CD3. This partnership underscores their commitment to advancing innovative immunotherapies for various cancers.-Fineline Info & Tech
